Drug Profile
Research programme: AIDS gene therapy - EUFETS
Latest Information Update: 20 Jul 2009
Price :
$50
*
At a glance
- Originator EUFETS
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 20 Jul 2009 Discontinued - Preclinical for HIV infections in Germany (unspecified route)
- 20 Jan 2005 Preclinical trials in HIV infections treatment in Germany (unspecified route)